Literature DB >> 28366759

MRI ductography of contrast agent distribution and leakage in normal mouse mammary ducts and ducts with in situ cancer.

Erica Markiewicz1, Xiaobing Fan1, Devkumar Mustafi1, Marta Zamora1, Suzanne D Conzen2, Gregory S Karczmar3.   

Abstract

High resolution 3D MRI was used to study contrast agent distribution and leakage in normal mouse mammary glands and glands containing in situ cancer after intra-ductal injection. Five female FVB/N mice (~19weeks old) with no detectable mammary cancer and eight C3(1) SV40 Tag virgin female mice (~15weeks old) with extensive in situ cancer were studied. A 34G, 45° tip Hamilton needle with a 25μL Hamilton syringe was inserted into the tip of the nipple and approximately 15μL of a Gadodiamide was injected slowly over 1min into the nipple and throughout the duct on one side of the inguinal gland. Following injection, the mouse was placed in a 9.4T MRI scanner, and a series of high resolution 3D T1-weighted images was acquired with a temporal resolution of 9.1min to follow contrast agent leakage from the ducts. The first image was acquired at about 12min after injection. Ductal enhancement regions detected in images acquired between 12 and 21min after contrast agent injection was five times smaller in SV40 mouse mammary ducts (p<0.001) than in non-cancerous FVB/N mouse mammary ducts, perhaps due to rapid washout of contrast agent from the SV40 ducts. The contrast agent washout rate measured between 12min and 90min after injection was ~20% faster (p<0.004) in SV40 mammary ducts than in FVB/N mammary ducts. These results may be due to higher permeability of the SV40 ducts, likely due to the presence of in situ cancers. Therefore, increased permeability of ducts may indicate early stage breast cancers.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  3D MRI; Contrast agent; Ductal injection; MRI ductography; Mouse mammary gland

Mesh:

Substances:

Year:  2017        PMID: 28366759      PMCID: PMC5531061          DOI: 10.1016/j.mri.2017.03.009

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  18 in total

1.  Can Radiologists Predict the Presence of Ductal Carcinoma In Situ and Invasive Breast Cancer?

Authors:  Shadi Aminololama-Shakeri; Chris I Flowers; Christine E McLaren; Dorota J Wisner; Jade de Guzman; Joan E Campbell; Lawrence W Bassett; Haydee Ojeda-Fournier; Karen Gerlach; Jonathan Hargreaves; Sarah L Elson; Hanna Retallack; Bonnie N Joe; Stephen A Feig; Colin J Wells
Journal:  AJR Am J Roentgenol       Date:  2017-02-15       Impact factor: 3.959

Review 2.  Ductography: how to and what if?

Authors:  S H Slawson; B A Johnson
Journal:  Radiographics       Date:  2001 Jan-Feb       Impact factor: 5.333

3.  Factors Associated With Rates of False-Positive and False-Negative Results From Digital Mammography Screening: An Analysis of Registry Data.

Authors:  Heidi D Nelson; Ellen S O'Meara; Karla Kerlikowske; Steven Balch; Diana Miglioretti
Journal:  Ann Intern Med       Date:  2016-01-12       Impact factor: 25.391

4.  Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast.

Authors:  Scott L Kominsky; Pedram Argani; Dorian Korz; Ella Evron; Venu Raman; Elizabeth Garrett; Alan Rein; Guido Sauter; Olli-P Kallioniemi; Saraswati Sukumar
Journal:  Oncogene       Date:  2003-04-03       Impact factor: 9.867

5.  Preclinical and clinical evaluation of intraductally administered agents in early breast cancer.

Authors:  Vered Stearns; Tsuyoshi Mori; Lisa K Jacobs; Nagi F Khouri; Edward Gabrielson; Takahiro Yoshida; Scott L Kominsky; David L Huso; Stacie Jeter; Penny Powers; Karineh Tarpinian; Regina J Brown; Julie R Lange; Michelle A Rudek; Zhe Zhang; Theodore N Tsangaris; Saraswati Sukumar
Journal:  Sci Transl Med       Date:  2011-10-26       Impact factor: 17.956

Review 6.  The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma.

Authors:  J E Green; M A Shibata; K Yoshidome; M L Liu; C Jorcyk; M R Anver; J Wigginton; R Wiltrout; E Shibata; S Kaczmarczyk; W Wang; Z Y Liu; A Calvo; C Couldrey
Journal:  Oncogene       Date:  2000-02-21       Impact factor: 9.867

7.  Detection of in situ mammary cancer in a transgenic mouse model: in vitro and in vivo MRI studies demonstrate histopathologic correlation.

Authors:  S A Jansen; S D Conzen; X Fan; T Krausz; M Zamora; S Foxley; J River; G M Newstead; G S Karczmar
Journal:  Phys Med Biol       Date:  2008-09-09       Impact factor: 3.609

8.  Ductal carcinoma in situ: X-ray fluorescence microscopy and dynamic contrast-enhanced MR imaging reveals gadolinium uptake within neoplastic mammary ducts in a murine model.

Authors:  Sanaz A Jansen; Tatjana Paunesku; Xiaobing Fan; Gayle E Woloschak; Stefan Vogt; Suzanne D Conzen; Thomas Krausz; Gillian M Newstead; Gregory S Karczmar
Journal:  Radiology       Date:  2009-11       Impact factor: 11.105

9.  Mammary cancer initiation and progression studied with magnetic resonance imaging.

Authors:  Xiaobing Fan; Devkumar Mustafi; Erica Markiewicz; Marta Zamora; James Vosicky; Abby Leinroth; Jeffrey Mueller; Kay Macleod; Suzanne D Conzen; Gregory S Karczmar
Journal:  Breast Cancer Res       Date:  2014-12-16       Impact factor: 6.466

10.  An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ.

Authors:  Fariba Behbod; Frances S Kittrell; Heather LaMarca; David Edwards; Sofia Kerbawy; Jessica C Heestand; Evelin Young; Purna Mukhopadhyay; Hung-Wen Yeh; D Craig Allred; Min Hu; Kornelia Polyak; Jeffrey M Rosen; Daniel Medina
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

View more
  1 in total

1.  Dynamic Enhanced Magnetic Resonance Imaging versus Ultrasonic Diffused Optical Tomography in Early Diagnosis of Breast Cancer.

Authors:  Feng Xue; Jie Jiang
Journal:  J Healthc Eng       Date:  2022-04-12       Impact factor: 3.822

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.